November 16, 2026

How PCORnet® Supports Patient-Centered Research on a Rare Form of Epilepsy

For families of children and young adults with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy, choosing the next treatment when multiple medications have failed to control seizures can be difficult.

To help those families and clinicians make informed decisions, a PCORI-funded PCORnet® Study is comparing epilepsy surgery with additional anti-seizure medications.

Led by Sandi Lam, MD, MBA, at Lurie Children’s Hospital, this retrospective observational study draws on the PCORnet® Common Data Model (CDM) and study-specific data, as well as embedded research and engagement expertise.

The study, Comparative Effectiveness of Epilepsy Surgery Versus Additional Anti-Seizure Medications for LGS, examines which treatment approach is more effective at reducing seizure-related emergency room visits and hospitalizations. Caregiver surveys will also assess outcomes related to behavior, communication, and quality of life.

Representative Data From 50 Million People Nationwide Provides Advantages for Rare Disease Research

Small, geographically dispersed patient populations can make it difficult to study treatment outcomes for rare diseases such as LGS. To support a national study across multiple sites, the LGS study team drew on PCORnet data resources reflecting everyday healthcare encounters involving more than 50 million people nationwide.

Complex and evolving definitions of LGS present another research challenge, making it difficult to identify patients consistently through electronic health records and interpret findings on treatment effectiveness.

To address this challenge, the study team used the PCORnet® CDM to develop and validate computable phenotypes, the standardized criteria for identifying patients with LGS across health systems.

Pediatric epileptologists (neurologists who specialize in epilepsy) and trained clinical research coordinators at seven study sites identified patients with LGS through their site’s electronic health records. Epileptologists at other participating sites independently confirmed each diagnosis, helping establish a reliable data set for computable phenotyping.

“Being able to reliably identify patients with LGS was crucial to our study,” said Dr. Lam. “The computable phenotypes we developed with the PCORnet® CDM can improve clinical diagnosis and support future large-scale studies to generate new insights into treatments and help improve quality of life for patients with LGS.”

Research-Ready Data Grounded in Local Clinical Context

Using the standardized criteria and the PCORnet® CDM, the study team is analyzing data from more than 10,000 patients across five PCORnet® Clinical Research Networks. These include PEDSnet, a pediatric network with a longitudinal data resource dating back to 2009.

The researchers are examining data from 2016 through 2024 to compare additional anti-seizure medication with surgery approaches, including vagus nerve stimulation and corpus callosotomy. The team is also looking at how the use of additional medication versus epilepsy surgery varies across healthcare systems.

Interpreting these data requires understanding how care is delivered and documented at each site.

Through PCORnet, the study team works with local clinicians and data teams to understand how information is recorded and standardized within clinical workflows. Their insights help researchers interpret what a medication entry means in the context of a patient’s treatment history and to identify meaningful decision points, such as when surgery may be considered.

Patient and Caregiver Partners Engaged Throughout the Study

“Families living with Lennox-Gastaut syndrome aren’t just recipients of research, they’re the ones who notice the small changes that matter and who live with the day-to-day reality researchers are trying to improve,” said Kathy Leavens, Senior Director of Programs at the Lennox-Gastaut Syndrome Foundation.

Patients, families, patient advocacy representatives, and clinicians helped plan this study, focusing on outcomes that matter in daily life and the treatment decisions that families face.

“When we bring their perspective and lived experience into the room alongside clinical expertise, we don’t just make research more human, we make it more accurate. This study accomplished that. There is real hope and momentum for making a difference for those living the journey now and those who come in the future,” said Leavens.

By combining standardized health data with engagement and research expertise, the PCORnet infrastructure is helping researchers generate evidence that can inform shared decision-making for rare diseases like LGS.

“One of our goals with this study was to give families and clinicians clearer information as they weigh whether additional medications or epilepsy surgery may offer the best next step for a child with Lennox-Gastaut syndrome,” said Dr. Lam. “We will continue working with our research partners to ensure the study results reach the LGS community in accessible ways so they can use the information to make better-informed treatment decisions and provide the best possible care for patients with this severe and complex lifelong disorder.”

Ready to partner with PCORnet for your patient-centered health research?

Contact the PCORnet® Front Door team to learn how the network can support your study.